<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01373229</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00026715</org_study_id>
    <secondary_id>RV0622</secondary_id>
    <nct_id>NCT01373229</nct_id>
  </id_info>
  <brief_title>Lenalidomide + Plerixafor in Previously Treated Chronic Lymphocytic Leukemia (CLL)</brief_title>
  <official_title>Lenalidomide in Combination With Plerixafor in Patients With Previously Treated Chronic Lymphocytic Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>David Rizzieri, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Celgene Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Genzyme, a Sanofi Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In research studies, lenalidomide (also called Revlimid) has shown some response in chronic
      lymphocytic leukemia (CLL); however, responses are usually partial responses that occur after
      several months of taking the study drug. It is thought that by adding the drug plerixafor
      (also called Mozobil) responses may be improved and/or occur sooner.

      The main purpose of this study is to determine the dose of plerixafor that is safe to use in
      combination with lenalidomide. The study will also look at the response rates of the
      combination of lenalidomide and plerixafor and the effect the study drugs have on CLL cells.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The combination of lenalidomide and plerixafor will be evaluated in this single institution,
      open label clinical study of subjects with relapsed chronic lymphocytic leukemia (CLL). The
      overall design of the phase 1 study includes up to three treatment &quot;stages.&quot;

      Each subject will receive lenalidomide 5mg by mouth daily beginning on cycle 1 day 1. If
      tolerated, the dose will be increased by 2.5mg every 7 days to a maximum dose of 10mg by
      mouth daily (Stage 1). Once the subject is stably maintained on a daily dose of lenalidomide
      of 10mg daily and the white blood cell (WBC) count is &lt;100.0 x 109 / L, and has been taking
      lenalidomide for at least 28 days, plerixafor will be added (Stage 2). In the dose escalation
      phase, 4 different doses of plerixafor in combination with lenalidomide will be studied in
      cohorts of 3 to 6 subjects each, following a standard &quot;3 + 3&quot; format:

        -  Cohort 1: plerixafor 0.24 mg/kg subcutaneous (SC) daily thrice weekly (Mon, Wed, Fri)

        -  Cohort 2: plerixafor 0.32 mg/kg SC daily thrice weekly (Mon, Wed, Fri)

        -  Cohort 3: plerixafor 0.42 mg/kg SC daily thrice weekly (Mon, Wed, Fri)

        -  Cohort 4: plerixafor 0.54 mg/kg SC daily thrice weekly (Mon, Wed, Fri) Plerixafor will
           be administered for 3 weeks of each cycle (days 1, 3, 5, 8, 10, 12, 15, 17, and 19)
           followed by a 1 week rest period. Lenalidomide dosing will be continuous.

      An interim assessment of response will be performed after 4 cycles of combination therapy:

        -  Subjects achieving a complete response (CR) by National Cancer Institute (NCI)-96
           criteria will continue lenalidomide monotherapy (plerixafor is discontinued) until
           disease progression.

        -  Subjects achieving a partial response (PR) will continue both lenalidomide and
           plerixafor. Additionally, rituximab 375mg/m2 will be added on day 1 of each subsequent
           cycle beginning with cycle 5, day 1 of combination therapy. (Stage 3). Treatment with
           the combination of lenalidomide and plerixafor will continue for a maximum of 12 cycles
           of combination therapy. Subjects may receive up to 8 doses of rituximab concurrent with
           lenalidomide and plerixafor on day 1 of each cycle. Subjects will then continue single
           agent lenalidomide until disease progression.

        -  Subjects with stable disease may continue lenalidomide and plerixafor at the discretion
           of the investigator and the subject. Rituximab 375 mg/m2 will be added on day 1 of each
           subsequent cycle. Treatment, dose, schedule, and duration are the same as for subjects
           achieving a PR.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 2012</start_date>
  <completion_date type="Actual">March 2015</completion_date>
  <primary_completion_date type="Actual">March 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Tolerated Dose</measure>
    <time_frame>4-16 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Response (Complete Response/Partial Response)</measure>
    <time_frame>at the end of 4 months of combination treatment and at 2 months after completion of therapy</time_frame>
    <description>NCI 96 Response Criteria
CR (Complete Response):
Lymphadenopathy = none &gt; 1.5cm Hepatomegaly = none Splenomegaly = none Blood lymphocytes = &lt;4000 per microliter Marrow = normocellular, &lt;30% lymphocytes, no B-lymphoid nodules. Platelet count = &gt;100,000 per microliter Hemoglobin = &gt;11.0 grams per deciliter Neutrophils = &gt;1500 per microliter
PR (Partial Response):
Lymphadenopathy = Decrease &gt;/= 50% Hepatomegaly = Decrease &gt;/= 50% Splenomegaly = Decrease &gt;/= 50% Blood lymphocytes = Decrease &gt;/= 50% from baseline Marrow = 50% reduction in marrow infiltrate or B-lymphoid nodules. Platelet count = &gt;100,000 per microliter or increase &gt;/= 50% over baseline Hemoglobin = &gt;11.0 grams per deciliter or increase &gt;/= 50% over baseline Neutrophils = &gt;1500 per microliter or increase &gt;/= 50% over baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival (PFS)</measure>
    <time_frame>time from day 1 of treatment to disease progression, death, or 2 years, whichever comes first</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>the time from day 1 of treatment to death or 2 years, whichever comes first</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction in Severity of B Symptoms</measure>
    <time_frame>at the end of stage 1 (lenalidomide alone), at the end of stage 2 (4 months of combination), and at 2 months post-completion of therapy</time_frame>
    <description>Reduction in the severity of the following B symptoms will be assessed: fever â‰¥ 101F, chills, night sweats, and anorexia with weight loss.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction in the Frequency of Blood and Platelet Transfusions</measure>
    <time_frame>4 weeks prior to therapy and in the 4 weeks following the completion of therapy</time_frame>
    <description>The change in number of transfusions from pre- to post-treatment will be calculated and summarized across all patients by giving the minimum, the 25th, 50th (median) and the 75th percentile and the maximum.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">21</enrollment>
  <condition>Leukemia, Lymphocytic, Chronic, B-Cell</condition>
  <arm_group>
    <arm_group_label>Lenalidomide + Plerixafor+ Rituximab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lenalidomide 5mg by mouth (PO) daily beginning cycle 1 day 1.
Stage 1: increase by 2.5mg every 7 days to a maximum dose of 10mg.
Stage 2: plerixafor will be added after 28 days of 10mg dose maintenance and white blood cell count (WBC) &lt;100.0 x 109 / L.
Dose cohorts of escalating subcutaneous (SC) thrice weekly plerixafor with continuous 10mg lenalidomide:
Cohort 1: 0.24 mg/kg
Cohort 2: 0.32 mg/kg
Cohort 3: 0.42 mg/kg
Cohort 4: 0.54 mg/kg
Stage 3: Rituximab 375mg/m2 will be added on day 1 of cycles 5-12, day 1 of combination therapy for subjects with PR.
Subjects will then continue single agent lenalidomide until disease progression.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lenalidomide + Plerixafor (+ Rituximab)</intervention_name>
    <description>Lenalidomide 5mg by mouth (PO) daily beginning cycle 1 day 1.
Stage 1: increase by 2.5mg every 7 days to a maximum dose of 10mg.
Stage 2: plerixafor will be added after 28 days of 10mg dose maintenance and white blood cell count (WBC) &lt;100.0 x 109 / L.
Dose cohorts of escalating subcutaneous (SC) thrice weekly plerixafor with continuous 10mg lenalidomide:
Cohort 1: 0.24 mg/kg
Cohort 2: 0.32 mg/kg
Cohort 3: 0.42 mg/kg
Cohort 4: 0.54 mg/kg
Stage 3: Rituximab 375mg/m2 will be added on day 1 of cycles 5-12, day 1 of combination therapy for subjects with PR.
Subjects will then continue single agent lenalidomide until disease progression.</description>
    <arm_group_label>Lenalidomide + Plerixafor+ Rituximab</arm_group_label>
    <other_name>Revlimid</other_name>
    <other_name>Mozobil</other_name>
    <other_name>Rituxan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed diagnosis of chronic lymphocytic leukemia (CLL) or Small
             lymphocytic lymphoma (SLL) as established by the National Cancer Institute (NCI)
             Working Group Response Criteria (NCI 96 Criteria).

          -  Received one or more prior therapies for CLL.

          -  Subjects must have symptomatic disease requiring therapy as defined by the protocol.

          -  &gt;/= 4 weeks from prior cancer therapy.

          -  Eastern Cooperative Oncology Group (ECOG) performance status of &lt;/= 2.

          -  All study subjects must be registered into the mandatory RevAssistÂ® program, and be
             willing and able to comply with the requirements of RevAssistÂ®.

        Exclusion Criteria:

          -  Prolymphocytic leukemia (PLL).

          -  Richter's (large cell) transformation.

          -  Prior allogeneic transplant within 12 months or prior allogeneic transplant &gt; 12
             months currently receiving immunosuppressants.

          -  Active autoimmune hemolytic anemia.

          -  Central nervous system (CNS) involvement.

          -  Chronic enteral corticosteroids &gt; 10mg prednisone or equivalent.

          -  Evidence of laboratory tumor lysis syndrome (TLS) by Cairo-Bishop Definition of Tumor
             Lysis Syndrome

          -  Use of any other experimental drug or therapy within 28 days of baseline

          -  Major surgery within 28 days of baseline.

          -  Known hypersensitivity to thalidomide.

          -  The development of erythema nodosum if characterized by a desquamating rash while
             taking thalidomide or similar drugs.

          -  Any prior use of lenalidomide.

          -  Known seropositive for or active viral infection with human immunodeficiency virus
             (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David A Rizzieri, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 12, 2011</study_first_submitted>
  <study_first_submitted_qc>June 13, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 14, 2011</study_first_posted>
  <results_first_submitted>January 25, 2017</results_first_submitted>
  <results_first_submitted_qc>July 26, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">February 5, 2018</results_first_posted>
  <last_update_submitted>July 26, 2017</last_update_submitted>
  <last_update_submitted_qc>July 26, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Duke University</investigator_affiliation>
    <investigator_full_name>David Rizzieri, MD</investigator_full_name>
    <investigator_title>Associate Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Chronic Lymphocytic Leukemia</keyword>
  <keyword>CLL</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lenalidomide</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Thalidomide</mesh_term>
    <mesh_term>JM 3100</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were recruited from the CLL clinic at Duke Medical Center from January 2012 to December 2013.</recruitment_details>
      <pre_assignment_details>21 subjects were consented to this study. Six (6) were screen failures; therefore, only 15 subjects began the treatment regimen which included a lenalidomide run-in phase. Three (3) subjects were unable to complete the run-in phase. Three (3) subjects died prior to completing stage 2, and so were not evaluable for DLT.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Lenalidomide + Plerixafor+ Rituximab</title>
          <description>Lenalidomide 5mg by mouth (PO) daily beginning cycle 1 day 1.
Stage 1: increase by 2.5mg every 7 days to a maximum dose of 10mg.
Stage 2: plerixafor will be added after 28 days of 10mg dose maintenance and white blood cell count (WBC) &lt;100.0 x 109 / L.
Dose cohorts of escalating subcutaneous (SC) thrice weekly plerixafor with continuous 10mg lenalidomide:
Cohort 1: 0.24 mg/kg
Cohort 2: 0.32 mg/kg
Stage 3: Rituximab 375mg/m2 will be added on day 1 of cycles 5-12, day 1 of combination therapy for subjects with PR.
Subjects will then continue single agent lenalidomide until disease progression.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Lenalidomide + Plerixafor+ Rituximab</title>
          <description>Lenalidomide 5mg by mouth (PO) daily beginning cycle 1 day 1.
Stage 1: increase by 2.5mg every 7 days to a maximum dose of 10mg.
Stage 2: plerixafor will be added after 28 days of 10mg dose maintenance and white blood cell count (WBC) &lt;100.0 x 109 / L.
Dose cohorts of escalating subcutaneous (SC) thrice weekly plerixafor with continuous 10mg lenalidomide:
Cohort 1: 0.24 mg/kg
Cohort 2: 0.32 mg/kg
Stage 3: Rituximab 375mg/m2 will be added on day 1 of cycles 5-12, day 1 of combination therapy for subjects with PR.
Subjects will then continue single agent lenalidomide until disease progression.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="15"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Maximum Tolerated Dose</title>
        <time_frame>4-16 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Lenalidomide + Plerixafor+ Rituximab</title>
            <description>Lenalidomide 5mg by mouth (PO) daily beginning cycle 1 day 1.
Stage 1: increase by 2.5mg every 7 days to a maximum dose of 10mg.
Stage 2: plerixafor will be added after 28 days of 10mg dose maintenance and white blood cell count (WBC) &lt;100.0 x 109 / L.
Dose cohorts of escalating subcutaneous (SC) thrice weekly plerixafor with continuous 10mg lenalidomide:
Cohort 1: 0.24 mg/kg
Cohort 2: 0.32 mg/kg
Stage 3: Rituximab 375mg/m2 will be added on day 1 of cycles 5-12, day 1 of combination therapy for subjects with PR.
Subjects will then continue single agent lenalidomide until disease progression.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Tolerated Dose</title>
          <units>mg/kg</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Response (Complete Response/Partial Response)</title>
        <description>NCI 96 Response Criteria
CR (Complete Response):
Lymphadenopathy = none &gt; 1.5cm Hepatomegaly = none Splenomegaly = none Blood lymphocytes = &lt;4000 per microliter Marrow = normocellular, &lt;30% lymphocytes, no B-lymphoid nodules. Platelet count = &gt;100,000 per microliter Hemoglobin = &gt;11.0 grams per deciliter Neutrophils = &gt;1500 per microliter
PR (Partial Response):
Lymphadenopathy = Decrease &gt;/= 50% Hepatomegaly = Decrease &gt;/= 50% Splenomegaly = Decrease &gt;/= 50% Blood lymphocytes = Decrease &gt;/= 50% from baseline Marrow = 50% reduction in marrow infiltrate or B-lymphoid nodules. Platelet count = &gt;100,000 per microliter or increase &gt;/= 50% over baseline Hemoglobin = &gt;11.0 grams per deciliter or increase &gt;/= 50% over baseline Neutrophils = &gt;1500 per microliter or increase &gt;/= 50% over baseline</description>
        <time_frame>at the end of 4 months of combination treatment and at 2 months after completion of therapy</time_frame>
        <population>Three (3) subjects were unable to complete the run-in phase. Three (3) subjects died prior to completing stage 2, and three (3) subjects were unable to complete 4 cycles of combination therapy. Therefore, only 6 subjects were analyzed for response.</population>
        <group_list>
          <group group_id="O1">
            <title>Lenalidomide + Plerixafor+ Rituximab</title>
            <description>Lenalidomide 5mg by mouth (PO) daily beginning cycle 1 day 1.
Stage 1: increase by 2.5mg every 7 days to a maximum dose of 10mg.
Stage 2: plerixafor will be added after 28 days of 10mg dose maintenance and white blood cell count (WBC) &lt;100.0 x 109 / L.
Dose cohorts of escalating subcutaneous (SC) thrice weekly plerixafor with continuous 10mg lenalidomide:
Cohort 1: 0.24 mg/kg
Cohort 2: 0.32 mg/kg
Stage 3: Rituximab 375mg/m2 will be added on day 1 of cycles 5-12, day 1 of combination therapy for subjects with PR.
Subjects will then continue single agent lenalidomide until disease progression.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Response (Complete Response/Partial Response)</title>
          <description>NCI 96 Response Criteria
CR (Complete Response):
Lymphadenopathy = none &gt; 1.5cm Hepatomegaly = none Splenomegaly = none Blood lymphocytes = &lt;4000 per microliter Marrow = normocellular, &lt;30% lymphocytes, no B-lymphoid nodules. Platelet count = &gt;100,000 per microliter Hemoglobin = &gt;11.0 grams per deciliter Neutrophils = &gt;1500 per microliter
PR (Partial Response):
Lymphadenopathy = Decrease &gt;/= 50% Hepatomegaly = Decrease &gt;/= 50% Splenomegaly = Decrease &gt;/= 50% Blood lymphocytes = Decrease &gt;/= 50% from baseline Marrow = 50% reduction in marrow infiltrate or B-lymphoid nodules. Platelet count = &gt;100,000 per microliter or increase &gt;/= 50% over baseline Hemoglobin = &gt;11.0 grams per deciliter or increase &gt;/= 50% over baseline Neutrophils = &gt;1500 per microliter or increase &gt;/= 50% over baseline</description>
          <population>Three (3) subjects were unable to complete the run-in phase. Three (3) subjects died prior to completing stage 2, and three (3) subjects were unable to complete 4 cycles of combination therapy. Therefore, only 6 subjects were analyzed for response.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression-free Survival (PFS)</title>
        <time_frame>time from day 1 of treatment to disease progression, death, or 2 years, whichever comes first</time_frame>
        <population>Subjects who experienced disease progression</population>
        <group_list>
          <group group_id="O1">
            <title>Lenalidomide + Plerixafor+ Rituximab</title>
            <description>Lenalidomide 5mg by mouth (PO) daily beginning cycle 1 day 1.
Stage 1: increase by 2.5mg every 7 days to a maximum dose of 10mg.
Stage 2: plerixafor will be added after 28 days of 10mg dose maintenance and white blood cell count (WBC) &lt;100.0 x 109 / L.
Dose cohorts of escalating subcutaneous (SC) thrice weekly plerixafor with continuous 10mg lenalidomide:
Cohort 1: 0.24 mg/kg
Cohort 2: 0.32 mg/kg
Stage 3: Rituximab 375mg/m2 will be added on day 1 of cycles 5-12, day 1 of combination therapy for subjects with PR.
Subjects will then continue single agent lenalidomide until disease progression.</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-free Survival (PFS)</title>
          <population>Subjects who experienced disease progression</population>
          <units>months</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11" spread="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival (OS)</title>
        <time_frame>the time from day 1 of treatment to death or 2 years, whichever comes first</time_frame>
        <population>Subjects who died on study</population>
        <group_list>
          <group group_id="O1">
            <title>Lenalidomide + Plerixafor+ Rituximab</title>
            <description>Lenalidomide 5mg by mouth (PO) daily beginning cycle 1 day 1.
Stage 1: increase by 2.5mg every 7 days to a maximum dose of 10mg.
Stage 2: plerixafor will be added after 28 days of 10mg dose maintenance and white blood cell count (WBC) &lt;100.0 x 109 / L.
Dose cohorts of escalating subcutaneous (SC) thrice weekly plerixafor with continuous 10mg lenalidomide:
Cohort 1: 0.24 mg/kg
Cohort 2: 0.32 mg/kg
Stage 3: Rituximab 375mg/m2 will be added on day 1 of cycles 5-12, day 1 of combination therapy for subjects with PR.
Subjects will then continue single agent lenalidomide until disease progression.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival (OS)</title>
          <population>Subjects who died on study</population>
          <units>months</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.5" spread="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Reduction in Severity of B Symptoms</title>
        <description>Reduction in the severity of the following B symptoms will be assessed: fever â‰¥ 101F, chills, night sweats, and anorexia with weight loss.</description>
        <time_frame>at the end of stage 1 (lenalidomide alone), at the end of stage 2 (4 months of combination), and at 2 months post-completion of therapy</time_frame>
        <population>Data were not collected and the Outcome will never be analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>Lenalidomide + Plerixafor+ Rituximab</title>
            <description>Lenalidomide 5mg by mouth (PO) daily beginning cycle 1 day 1.
Stage 1: increase by 2.5mg every 7 days to a maximum dose of 10mg.
Stage 2: plerixafor will be added after 28 days of 10mg dose maintenance and white blood cell count (WBC) &lt;100.0 x 109 / L.
Dose cohorts of escalating subcutaneous (SC) thrice weekly plerixafor with continuous 10mg lenalidomide:
Cohort 1: 0.24 mg/kg
Cohort 2: 0.32 mg/kg
Stage 3: Rituximab 375mg/m2 will be added on day 1 of cycles 5-12, day 1 of combination therapy for subjects with PR.
Subjects will then continue single agent lenalidomide until disease progression.</description>
          </group>
        </group_list>
        <measure>
          <title>Reduction in Severity of B Symptoms</title>
          <description>Reduction in the severity of the following B symptoms will be assessed: fever â‰¥ 101F, chills, night sweats, and anorexia with weight loss.</description>
          <population>Data were not collected and the Outcome will never be analyzed</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Reduction in the Frequency of Blood and Platelet Transfusions</title>
        <description>The change in number of transfusions from pre- to post-treatment will be calculated and summarized across all patients by giving the minimum, the 25th, 50th (median) and the 75th percentile and the maximum.</description>
        <time_frame>4 weeks prior to therapy and in the 4 weeks following the completion of therapy</time_frame>
        <population>Data were not collected and the Outcome will never be analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>Lenalidomide + Plerixafor+ Rituximab</title>
            <description>Lenalidomide 5mg by mouth (PO) daily beginning cycle 1 day 1.
Stage 1: increase by 2.5mg every 7 days to a maximum dose of 10mg.
Stage 2: plerixafor will be added after 28 days of 10mg dose maintenance and white blood cell count (WBC) &lt;100.0 x 109 / L.
Dose cohorts of escalating subcutaneous (SC) thrice weekly plerixafor with continuous 10mg lenalidomide:
Cohort 1: 0.24 mg/kg
Cohort 2: 0.32 mg/kg
Stage 3: Rituximab 375mg/m2 will be added on day 1 of cycles 5-12, day 1 of combination therapy for subjects with PR.
Subjects will then continue single agent lenalidomide until disease progression.</description>
          </group>
        </group_list>
        <measure>
          <title>Reduction in the Frequency of Blood and Platelet Transfusions</title>
          <description>The change in number of transfusions from pre- to post-treatment will be calculated and summarized across all patients by giving the minimum, the 25th, 50th (median) and the 75th percentile and the maximum.</description>
          <population>Data were not collected and the Outcome will never be analyzed</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Lenalidomide + Plerixafor+ Rituximab</title>
          <description>Lenalidomide 5mg by mouth (PO) daily beginning cycle 1 day 1.
Stage 1: increase by 2.5mg every 7 days to a maximum dose of 10mg.
Stage 2: plerixafor will be added after 28 days of 10mg dose maintenance and white blood cell count (WBC) &lt;100.0 x 109 / L.
Dose cohorts of escalating subcutaneous (SC) thrice weekly plerixafor with continuous 10mg lenalidomide:
Cohort 1: 0.24 mg/kg
Cohort 2: 0.32 mg/kg
Stage 3: Rituximab 375mg/m2 will be added on day 1 of cycles 5-12, day 1 of combination therapy for subjects with PR.
Subjects will then continue single agent lenalidomide until disease progression.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Hemolysis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death NOS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infections and infestations - Other, specify</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>White blood cell decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dysphasia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Thromboembolic event</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="14" subjects_affected="13" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Blood and lymphatic system disorders - Other, specify</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Lymph node pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear and labyrinth disorders - Other, specify</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Hearing impaired</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Blurred vision</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Dry eye</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Eye disorders - Other, specify</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Anal ulcer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Gastrointestinal disorders - Other, specify</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Stomach pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Edema limbs</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="12" subjects_affected="9" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>General disorders and administration site conditions - Other, specify</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic reaction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Cytokine release syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infections and infestations - Other, specify</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Creatinine increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" events="27" subjects_affected="13" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" events="16" subjects_affected="11" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Chest wall pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Generalized muscle weakness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Joint range of motion decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Concentration impairment</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Extrapyramidal disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Paresthesia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary frequency</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Urinary urgency</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Reproductive system and breast disorders - Other, specify</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Hoarseness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Respiratory, thoracic and mediastinal disorders - Other, specify</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Rash maculo-papular</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Skin and subcutaneous tissue disorders - Other, specify</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hot flashes</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Danielle Brander, MD</name_or_title>
      <organization>Duke University Medical Center</organization>
      <phone>919-286-6897</phone>
      <email>danielle.brander@duke.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

